TY - JOUR
T1 - Immunolocalization of epidermal growth factor receptor and cerbB-2 oncogene product in human ovarian carcinoma
AU - Ito, Kiyoshi
AU - Sasano, Hironobu
AU - Ozawa, Nobuyoshi
AU - Sato, Sinji
AU - Silverberg, Steven G.
AU - Yajima, Akira
PY - 1992/10
Y1 - 1992/10
N2 - Abnormalities of epidermal growth factor receptor (EGFR) and c-erbB-2 have been demonstrated to be correlated with aggressive biologic behavior in a variety of human cancers. To analyze the possible roles of these oncogenes in ovarian neoplasms, immunolocalization of EGFR and c-erbB-2 oncogene product was performed in 45 cases of human ovarian mucinous and serous cystadenomas, carcinomas of low malignant potential (LMP), and invasive carcinomas by employing antibodies against these oncogene products. EGFR immunoreactivity was present in 15 of 35 LMP and invasive carcinomas and 1 of 10 cystadenomas. On the contrary, immunoreactivity of p185, which is an oncogene product of c-erbB-2, was detected only in five cases of carcinoma and in no benign cystadenoma. These results indicate that EGFR may be involved in the neoplastic process in epithelial ovarian adenocarcinoma, especially mucinous carcinoma, but involvement of c-erbB-2 is probably not as prevalent as considered previously. Four of the five cases immunohistochemically positive for p185 were also positive for EGFR, which suggests that expression of EGFR and p185 is to some extent correlated in human ovarian carcinoma.
AB - Abnormalities of epidermal growth factor receptor (EGFR) and c-erbB-2 have been demonstrated to be correlated with aggressive biologic behavior in a variety of human cancers. To analyze the possible roles of these oncogenes in ovarian neoplasms, immunolocalization of EGFR and c-erbB-2 oncogene product was performed in 45 cases of human ovarian mucinous and serous cystadenomas, carcinomas of low malignant potential (LMP), and invasive carcinomas by employing antibodies against these oncogene products. EGFR immunoreactivity was present in 15 of 35 LMP and invasive carcinomas and 1 of 10 cystadenomas. On the contrary, immunoreactivity of p185, which is an oncogene product of c-erbB-2, was detected only in five cases of carcinoma and in no benign cystadenoma. These results indicate that EGFR may be involved in the neoplastic process in epithelial ovarian adenocarcinoma, especially mucinous carcinoma, but involvement of c-erbB-2 is probably not as prevalent as considered previously. Four of the five cases immunohistochemically positive for p185 were also positive for EGFR, which suggests that expression of EGFR and p185 is to some extent correlated in human ovarian carcinoma.
KW - C-erbB-2
KW - EGFR
KW - Immunohistochemistry
KW - Oncogenes
KW - Ovarian carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0026707922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026707922&partnerID=8YFLogxK
U2 - 10.1097/00004347-199210000-00002
DO - 10.1097/00004347-199210000-00002
M3 - Article
C2 - 1356938
AN - SCOPUS:0026707922
VL - 11
SP - 253
EP - 257
JO - International Journal of Gynecological Pathology
JF - International Journal of Gynecological Pathology
SN - 0277-1691
IS - 4
ER -